Adagene Net Worth
Adagene Net Worth Breakdown | ADAG |
Adagene Net Worth Analysis
Adagene's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Adagene's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Adagene's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Adagene's net worth analysis. One common approach is to calculate Adagene's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Adagene's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Adagene's net worth. This approach calculates the present value of Adagene's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Adagene's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Adagene's net worth. This involves comparing Adagene's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Adagene's net worth relative to its peers.
Enterprise Value |
|
To determine if Adagene is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Adagene's net worth research are outlined below:
| Adagene generated a negative expected return over the last 90 days | |
| Adagene has high historical volatility and very poor performance | |
| Adagene has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 18.11 M. Net Loss for the year was (18.95 M) with profit before overhead, payroll, taxes, and interest of 10.18 M. | |
| Adagene currently holds about 168.04 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from zacks.com: Is Adagene Stock Outpacing Its Medical Peers This Year |
Adagene uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Adagene. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adagene's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Adagene's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adagene is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adagene backward and forwards among themselves. Adagene's institutional investor refers to the entity that pools money to purchase Adagene's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royal Bank Of Canada | 2024-06-30 | 8.3 K | Ubs Group Ag | 2024-06-30 | 164 | Qube Research & Technologies | 2024-06-30 | 47.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Springbok Capital Management, Llc | 2024-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Artal Group S A | 2024-06-30 | 0.0 | Wuxi Apptec Co Ltd | 2024-09-30 | 4 M | Fidelity International Ltd | 2024-06-30 | 3.8 M | Sc China Holding Ltd | 2024-06-30 | 1.3 M | Fmr Inc | 2024-09-30 | 1.3 M |
Follow Adagene's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 108.46 M.Market Cap |
|
Project Adagene's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.16) | (0.17) | |
| Return On Capital Employed | (0.28) | (0.30) | |
| Return On Assets | (0.16) | (0.17) | |
| Return On Equity | (0.27) | (0.28) |
When accessing Adagene's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Adagene's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Adagene's profitability and make more informed investment decisions.
Evaluate Adagene's management efficiency
Adagene has return on total asset (ROA) of (0.1959) % which means that it has lost $0.1959 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.457) %, meaning that it created substantial loss on money invested by shareholders. Adagene's management efficiency ratios could be used to measure how well Adagene manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.17. The current Return On Capital Employed is estimated to decrease to -0.3. At this time, Adagene's Non Current Assets Total are most likely to increase significantly in the upcoming years. The Adagene's current Non Currrent Assets Other is estimated to increase to about 89.1 K, while Return On Tangible Assets are projected to decrease to (0.17).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.63 | 1.71 | |
| Tangible Book Value Per Share | 1.63 | 1.71 | |
| Enterprise Value Over EBITDA | 0.27 | 0.28 | |
| Price Book Value Ratio | 1.18 | 1.24 | |
| Enterprise Value Multiple | 0.27 | 0.28 | |
| Price Fair Value | 1.18 | 1.24 | |
| Enterprise Value | -4 M | -3.8 M |
Evaluating the management effectiveness of Adagene allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Adagene Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 30.8536 | Revenue 815.7 K | Quarterly Revenue Growth (0.85) | Revenue Per Share 0.019 | Return On Equity (0.46) |
Adagene Corporate Filings
6K | 7th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 24th of September 2024 Other Reports | ViewVerify | |
F3 | 1st of March 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Adagene Earnings per Share Projection vs Actual
Adagene Corporate Management
| Alexander Goergen | VP Development | Profile | |
| Guizhong Liu | Head Pharmacology | Profile | |
| Xiaohong She | Senior Operations | Profile | |
| Ling Zhou | Head Resources | Profile | |
| Man MBA | CFO Director | Profile | |
| Qinghai Zhao | Chief Officer | Profile | |
| Fangyong Du | Chief Officer | Profile |
Already Invested in Adagene?
The danger of trading Adagene is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adagene is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adagene. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adagene is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Adagene is a strong investment it is important to analyze Adagene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adagene's future performance. For an informed investment choice regarding Adagene Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adagene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Adagene Stock please use our How to Invest in Adagene guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adagene. If investors know Adagene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adagene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.72) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.85) | Return On Assets (0.20) | Return On Equity (0.46) |
The market value of Adagene is measured differently than its book value, which is the value of Adagene that is recorded on the company's balance sheet. Investors also form their own opinion of Adagene's value that differs from its market value or its book value, called intrinsic value, which is Adagene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adagene's market value can be influenced by many factors that don't directly affect Adagene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adagene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Adagene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adagene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.